LOS ANGELES, March 29, 2018 -- US based company Earth Healthcare offers a new Cannabis DNA Test Kit. Earth Healthcare's patent-pending Cannabis test kit, CANNA DNA Test Kit allows Earth Healthcare labs to analyze your genetic markers to determine your body's natural inclination to accept cannabinoids as medicine - whether the cannabinoids are produced endogenously, from plants or synthetically. This approach takes the guesswork out of medical cannabis use, offering you personalized treatment options that will optimize efficacy and minimize unintended effects.
|
|||||
We all have a different DNA makeup; our DNA proves it. That is why our body processes everything its own individual way, including cannabis. Would you like to know what your DNA says about how your body will react when you use cannabis?
Cannabinoids are such a useful and unique medicine to help restore homeostasis in the body because it is cannabinoids that are naturally produced in the body (endogenously) that we rely on for homeostasis. As a result, many imbalances and ailments can be restored from the use of exogenous cannabinoids, produced outside the body.
With the rise in medical cannabis use for a variety of medical conditions including cancer, autoimmune disorders, and dietary issues, Earth Healthcare's CANNA DNA genetic test kit will allow people to know how their body will react to it. This approach will take the guesswork out of cannabis use, offering personalized treatment recommendations that optimize efficacy and minimize unintended effects.
CANNA DNA Test Kit can target symptom relief, and the results can be customized for patients with symptom-relief recommendations specifically in the areas of Anxiety, Appetite, Stress, Insomnia, Nausea, and Pain.
Earth Healthcare's kits are available online at EarthHealthcare.com, dispensaries, and physicians offices. The kits include; sample-collection swabs, instructions, and a pre-addressed, stamped envelope. The samples are mailed to Earth Healthcare's CLIA-accredited and CAP-certified partner laboratory, where they analyze your DNA and compile a customized report. The report includes a cannabis-specific genomic profile, identifying how your body metabolizes Delta-9 tetrahydrocannabinol (THC) and cannabidiol (CBD), and recommendations of cannabis varieties best suited to your body chemistry and specific needs.
Scientific research continues to validate its efficacy for an expanding spectrum of illnesses and conditions. Yet, doctors have been limited to recommending cannabis without having supportive data to allow them to prescribe the medicine safely and effectively, until now.
Visit Earth Healthcare's Website to get more information or to order a kit at: www.earthhealthcare.com
Company: Earth Healthcare
Media Contact: Nicole Lenz
Los Angeles, CA
[email protected]
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/92addbb0-047c-4121-9e13-31f0f70c1b84


Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 



